Structure-activity relationship of 3-methyl-1-phenyl-2-pyrazolin-5-one (edaravone).
about
Protective effect of Edaravone against hypoxia-induced cytotoxicity in osteoblasts MC3T3-E1 cells.The edaravone and 3-n-butylphthalide ring-opening derivative 10b effectively attenuates cerebral ischemia injury in ratsEffects of edaravone on amyloid-β precursor protein processing in SY5Y-APP695 cells.Tautomeric forms study of 1H-(2'-pyridyl)-3-methyl-5-hydroxypyrazole and 1H-(2'-pyridyl)-3-phenyl-5-hydroxypyrazole. Synthesis, structure, and cytotoxic activity of their complexes with palladium(II) ions.MCI-186 administered to the maternal circulation inhibits fetal brain injury resulting from total umbilical cord occlusion in the chronically instrumented fetal lamb.Attenuation of ischemia/reperfusion-induced ovarian damage in rats: does edaravone offer protection?Changes of expression of glucose transporters in the fetal lamb brain after MCI-186 administration to the maternal circulation with 10-min persistent umbilical cord occlusion.The novel antioxidant edaravone: from bench to bedside.The production of hydroxyl radicals in the fetal lamb brain resulting from occlusion of the umbilical circulation and the transplacental effect of MCI-186 to inhibit hydroxyl radical production.Impact of antioxidants on seminal vesicles function and fertilizing potential in diabetic rats.How is edaravone effective against acute ischemic stroke and amyotrophic lateral sclerosis?Iodine-catalyzed sulfenylation of pyrazolones using dimethyl sulfoxide as an oxidant.One-flask synthesis of pyrazolone thioethers involving catalyzed and uncatalyzed thioetherification pathways of pyrazolones.
P2860
Q35848920-C1A21BAA-D266-49A7-8D39-EF772891F840Q36044786-7FC973D2-5571-49B5-AC96-BD66233F2F2CQ39209409-88C55CEE-14EC-4927-9A3F-59FEED61390FQ39775092-17AC0A8E-B8A5-4802-9F25-A81C8405B426Q42504448-C2F285C0-BA53-494E-9BC5-595EA39EC9F2Q44024185-1F691DDA-C69D-4556-B50E-FFD4A10B8A3DQ45918021-0AAF8CC0-CD90-4624-B448-A6753C53BBABQ46591722-8126B1C2-BC28-41A4-A793-992D56D28535Q46913661-CA1103F5-B18D-4CF5-81A6-07F3E1BB4F95Q47109707-573B06E9-6E3C-4CA3-9996-B568E043D0CDQ47700268-F51585A5-7F44-4D6E-B676-854378001ABFQ50200220-FFF818B3-FA36-4977-86EF-AA7E583BB577Q50497875-509B8E6D-06B1-4D24-8549-EFE4ADA80369
P2860
Structure-activity relationship of 3-methyl-1-phenyl-2-pyrazolin-5-one (edaravone).
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Structure-activity relationship of 3-methyl-1-phenyl-2-pyrazolin-5-one (edaravone).
@en
Structure-activity relationship of 3-methyl-1-phenyl-2-pyrazolin-5-one
@nl
type
label
Structure-activity relationship of 3-methyl-1-phenyl-2-pyrazolin-5-one (edaravone).
@en
Structure-activity relationship of 3-methyl-1-phenyl-2-pyrazolin-5-one
@nl
prefLabel
Structure-activity relationship of 3-methyl-1-phenyl-2-pyrazolin-5-one (edaravone).
@en
Structure-activity relationship of 3-methyl-1-phenyl-2-pyrazolin-5-one
@nl
P2093
P2860
P1433
P1476
Structure-activity relationship of 3-methyl-1-phenyl-2-pyrazolin-5-one (edaravone).
@en
P2093
Hiroyoshi Nishi
Katsuhiko Iseki
Kazutoshi Watanabe
Satoshi Yuki
Toshiaki Watanabe
Yasuhiro Morinaka
P2860
P304
P356
10.1179/135100003225001520
P577
2003-01-01T00:00:00Z